Sanofi Net Income 2010-2024 | SNY

Sanofi annual/quarterly net income history and growth rate from 2010 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Sanofi net income for the quarter ending September 30, 2024 was $3.095B, a 12.63% increase year-over-year.
  • Sanofi net income for the twelve months ending September 30, 2024 was $4.914B, a 49.22% decline year-over-year.
  • Sanofi annual net income for 2023 was $5.844B, a 33.73% decline from 2022.
  • Sanofi annual net income for 2022 was $8.82B, a 19.79% increase from 2021.
  • Sanofi annual net income for 2021 was $7.362B, a 47.66% decline from 2020.
Sanofi Annual Net Income
(Millions of US $)
2023 $5,844
2022 $8,820
2021 $7,362
2020 $14,066
2019 $3,143
2018 $5,085
2017 $9,533
2016 $5,211
2015 $4,760
2014 $5,836
2013 $4,937
2012 $6,388
2011 $8,265
2010 $7,597
2009 $7,937
Sanofi Quarterly Net Income
(Millions of US $)
2024-09-30 $3,095
2024-06-30 $1,199
2024-03-31 $1,230
2023-12-31 $-610
2023-09-30 $2,748
2023-06-30 $1,565
2023-03-31 $2,141
2022-12-31 $3,224
2022-09-30 $2,091
2022-06-30 $1,250
2022-03-31 $2,255
2021-09-30 $2,732
2021-06-30
2021-03-31 $1,888
2020-09-30 $2,282
2020-03-31 $1,857
2019-09-30 $1,964
2019-03-31 $1,291
2018-03-31 $1,249
2017-12-31 $475
2017-09-30 $1,842
2017-06-30 $1,141
2017-03-31 $6,076
2016-12-31 $836
2016-09-30 $1,868
2016-06-30 $1,308
2016-03-31 $1,199
2015-09-30 $1,811
2015-06-30 $1,440
2014-06-30 $1,066
2013-06-30 $580
2012-06-30 $1,505
2012-03-31 $2,414
2011-12-31 $1,887
2011-09-30 $2,803
2011-06-30 $1,453
2011-03-31 $3,187
2010-12-31 $595
2010-09-30 $2,219
2010-06-30 $2,219
2010-03-31 $3,204
2009-12-31 $1,658
2009-09-30 $3,290
2009-06-30 $3,227
2009-03-31 $2,817
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $121.714B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $759.263B 78.64
Novo Nordisk (NVO) Denmark $487.660B 35.17
Johnson & Johnson (JNJ) United States $372.700B 15.12
AbbVie (ABBV) United States $321.213B 16.91
Merck (MRK) United States $254.507B 16.91
Novartis AG (NVS) Switzerland $214.211B 14.24
AstraZeneca (AZN) United Kingdom $207.865B 17.69
Pfizer (PFE) United States $146.322B 10.01
Innoviva (INVA) United States $1.197B 9.96